UNIVEC Receives FDA 510(k) Clearance for its New Bifurcated Safety Needle Specifically Designed for U.S. and International Smallpox Vaccine Programs
(EMAILWIRE.COM, March 26, 2002 ) FARMINGDALE, N.Y. -- Farmingdale-based Univec, Inc., (OTCBB:UNVC - news) a leading manufacturer of patented auto-disable and safety syringes, distributor of physician samples and medical waste management technology, today announced FDA 510(k) clearance for its new Bifurcated Safety Needle. Univec's Bifurcated Safety Needle was specifically designed to meet the U.S. Government requirements for safe administration of the smallpox vaccine.
Univec's patented Bifurcated Safety Needles are the only bifurcated needles available that employ a sliding sheath mechanism that complies with the U.S. Needle Stick Law and OSHA regulations to effectively reduce the risk of accidental needle sticks.
According to Joel Schoenfeld, Univec's Chairman, and inventor of the Bifurcated Safety Needle, "Syringe and needle device manufactures have an obligation to the U.S. government and the people we serve, to offer safety devices that comply with the U.S. Needle Stick Law and OSHA requirements to protect patients and healthcare workers, and the new Univec Bifurcated Safety Needle does that."
This new device continues to add to the growth of products and services that Univec has in its pipeline of new products for safer health products to patients and caregivers worldwide.
About Univec
Founded in 1992, Univec is considered one of the leading innovators in the design and production of auto-disable and safety syringes, and with it's acquisition of Physician and Pharmaceutical Services, Inc. and Thermal Waste Technologies Inc., provides safe delivery of physician samples and disposal of infectious medical waste. The Company has production facilities in Portugal, South Korea, China, Belgium and the U.S., and has licensed its technology to Terumo of Belgium; a subsidiary of Terumo Japan, the leading producer of syringes outside the U.S. Univec distributes its products in 80 countries.
Forward Looking Statements
This document contains forward-looking statements based on current expectations that could be affected by the risks and uncertainties involved in Univec's business. These risks and uncertainties include, but are not limited to, the risks described from time to time in Univec's reports to the Securities and Exchange Commission, which include Univec's Annual Report on Form 10-K. Subsequent written or oral statements attributable to Univec or persons acting on its behalf are expressly qualified in their entirety by the cautionary statements in this document and those in Univec's reports filed with the SEC.
Contact:
G. Edward Kalbaugh
Allegent Growth Strategies International
516-364-7034 or e-mail gekalbaugh@allegentgsi.com
Univec's patented Bifurcated Safety Needles are the only bifurcated needles available that employ a sliding sheath mechanism that complies with the U.S. Needle Stick Law and OSHA regulations to effectively reduce the risk of accidental needle sticks.
According to Joel Schoenfeld, Univec's Chairman, and inventor of the Bifurcated Safety Needle, "Syringe and needle device manufactures have an obligation to the U.S. government and the people we serve, to offer safety devices that comply with the U.S. Needle Stick Law and OSHA requirements to protect patients and healthcare workers, and the new Univec Bifurcated Safety Needle does that."
This new device continues to add to the growth of products and services that Univec has in its pipeline of new products for safer health products to patients and caregivers worldwide.
About Univec
Founded in 1992, Univec is considered one of the leading innovators in the design and production of auto-disable and safety syringes, and with it's acquisition of Physician and Pharmaceutical Services, Inc. and Thermal Waste Technologies Inc., provides safe delivery of physician samples and disposal of infectious medical waste. The Company has production facilities in Portugal, South Korea, China, Belgium and the U.S., and has licensed its technology to Terumo of Belgium; a subsidiary of Terumo Japan, the leading producer of syringes outside the U.S. Univec distributes its products in 80 countries.
Forward Looking Statements
This document contains forward-looking statements based on current expectations that could be affected by the risks and uncertainties involved in Univec's business. These risks and uncertainties include, but are not limited to, the risks described from time to time in Univec's reports to the Securities and Exchange Commission, which include Univec's Annual Report on Form 10-K. Subsequent written or oral statements attributable to Univec or persons acting on its behalf are expressly qualified in their entirety by the cautionary statements in this document and those in Univec's reports filed with the SEC.
Contact:
G. Edward Kalbaugh
Allegent Growth Strategies International
516-364-7034 or e-mail gekalbaugh@allegentgsi.com
Contact Information:
Univec
G. Edward Kalbaugh
Tel:
Email us
This is a press release. Press release distribution and press release services by EmailWire.Com: http://www.emailwire.com/us-press-release-distribution.php.
Univec
G. Edward Kalbaugh
Tel:
Email us
This is a press release. Press release distribution and press release services by EmailWire.Com: http://www.emailwire.com/us-press-release-distribution.php.
|
Private Equity, Angel Investing
Equity Alliance / Private Equity, Angel Investing, / IPO, Venture Capital & IR services / Equity Alliance International Equityallianceir.com Penny Stocks to Watch Sign up for hot penny stock picks Gains of 500%+ possible! Premiumstockpicks.com/landing/ Your text Ads & PR Text Ads plus unlimited press releases, One release featured/Day for only $575 per month. Read more on Text Ads & PR Your text Ads Here! Text Ads are only $289 per month. Ads are placed same day. More on Text Ads Advertising |